Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Conditions:   Non Small Cell Lung Cancer;   Advanced Solid Tumor;   Metastatic Melanoma;   Metastatic Head and Neck Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Colorectal Cancer;   Sarcomas;   Metastatic Prostate Cancer Interventions:   Drug: ONC-392;   Drug: Pembrolizumab Sponsor:   OncoImmune, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials